Evaluation of a library of FDA-approved drugs for their ability to potentiate antibiotics against multidrug-resistant gram-negative pathogens

Charlotte Hind*, Christopher G. Dowson, J. Mark Sutton, Thomas Jackson, Melanie Clifford, R. Colin Garner, Lloyd Czaplewski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

The Prestwick library was screened for antibacterial activity or "antibiotic resistance breaker" (ARB) potential against four species of Gram-negative pathogens. Discounting known antibacterials, the screen identified very few ARB hits, which were strain/drug specific. These ARB hits included antimetabolites (zidovudine, floxuridine, didanosine, and gemcitabine), anthracyclines (daunorubicin, mitoxantrone, and epirubicin), and psychoactive drugs (gabapentin, fluspirilene, and oxethazaine). These findings suggest that there are few approved drugs that could be directly repositioned as adjunct antibacterials, and these will need robust testing to validate efficacy.

Original languageEnglish
Article numbere00769-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number8
DOIs
Publication statusPublished - 2019

Bibliographical note

Publisher Copyright:
© Crown copyright 2019.

Keywords

  • Antibiotic resistance breakers
  • Antimicrobial combinations
  • Repurposing

Fingerprint

Dive into the research topics of 'Evaluation of a library of FDA-approved drugs for their ability to potentiate antibiotics against multidrug-resistant gram-negative pathogens'. Together they form a unique fingerprint.

Cite this